Drugmaker Teva Pharmaceuticals fined $500M by European regulators

Oct. 31 (UPI) -- The European Commission fined Teva Pharmaceuticals $503 million for delaying competition posed by rival generic drugmakers, the company's second major financial penalty this month.

The multinational drug manufacturer headquartered in Israel "abusively disparaged a competing drug," used to treat multiple sclerosis, the commission said in a statement.

Advertisement